Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05361174 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
A Phase 1 study of Metastatic Melanoma and Unresectable Melanoma, sponsored by Iovance Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 10
- Study locations
NCT05361174: Recruiting Phase 1 study of Metastatic Melanoma and Unresectable Melanoma, sponsored by Iovance Biotherapeutics.
NCT05361174 is a Phase 1 study of Metastatic Melanoma and Unresectable Melanoma that is actively recruiting participants, run by Iovance Biotherapeutics. The registered enrollment target is 53 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (36% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05361174, a Phase 1 study of Metastatic Melanoma and Unresectable Melanoma, is actively recruiting participants, sponsored by Iovance Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Primary Outcome
The safety of IOV-4001 will be assessed based on the totality of dose-limiting toxicity (DLT) and adverse event (AE) data collected during this phase
Conditions Studied
Interventions
- BIOLOGICAL IOV-4001
Study Locations (10)
Florida
- Sylvester Comprehensive Cancer Center - Miami
- Orlando Health Cancer Institute - Orlando
- Moffitt Cancer Center - Tampa
California
- The Angeles Clinic and Research Institute - Los Angeles
Kansas
- The University of Kansas Cancer Center - Westwood
Kentucky
- University of Louisville - Louisville
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- University of Cincinnati - Cincinnati
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2022-07-20 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT05361174 shows while recruiting
NCT05361174 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (36% lower).
The record links to 4 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 1 intervention - of which IOV-4001 is the first listed.
NCT05361174 lists 10 locations in 8 states (Florida, California, Kansas).
Frequently Asked Questions
What is clinical trial NCT05361174 about?
NCT05361174 is a clinical study titled "A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer". This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
What is the current status of trial NCT05361174?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2022-07-20. Estimated completion is 2027-06.
What conditions does trial NCT05361174 study?
This clinical trial studies the following conditions: Metastatic Melanoma, Unresectable Melanoma, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT05361174?
The interventions under investigation include: IOV-4001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05361174?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05361174 being conducted?
This trial has 10 study locations across California, Florida, Kansas, Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05361174's enrollment target sits among peer trials
53 32nd of 91 higher than 60 of 91 other Metastatic Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
RECRUITING · Phase 1
-
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
RECRUITING · Phase 1
-
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
RECRUITING · Phase 1
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI